Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...

Synapticure, a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has ...

Therapists can’t be around for their patients 24/7. One startup is betting AI can be the solution. When trained with clinical ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...

Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...

Atlas Venture, one of biotech's go-to VC firms, is eyeing a $450 million 14th fund, partner Bruce Booth said in the firm’s ...

Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic ...

New hepatitis D treatment data from Vir Biotechnology and Bluejay Therapeutics shows promising results in reducing viral levels. Both companies plan further trials, with Vir targeting Phase 3 in 2025.

Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.

The FDA on Monday offered new draft guidance to help drugmakers understand the nuts and bolts of FDA processes for developing and submitting an application for a new cell or gene therapy, from pre-IND ...